Baidu
map

European Heart Journal:ESC提出减少污染空气暴露策略

2014-12-16 高晓方 译 医学论坛网

欧洲心脏病学会(ESC)指出,在心血管疾病预防和管理中,应将空气污染视为一种重要的可调节危险因素,并应与患者就空气污染暴露展开交流。全文12月9日在线发表于《欧洲心脏杂志》(European Heart Journal)。 空气污染与心血管疾病的关联性 以爱丁堡大学Newby博士为首的专家小组探讨了环境空气污染与心血管疾病的相关性和机制,并对医生如何劝告高危患者尽可能减

欧洲心脏病学会(ESC)指出,在心血管疾病预防和管理中,应将空气污染视为一种重要的可调节危险因素,并应与患者就空气污染暴露展开交流。全文12月9日在线发表于《欧洲心脏杂志》(European Heart Journal)。

空气污染与心血管疾病的关联性

以爱丁堡大学Newby博士为首的专家小组探讨了环境空气污染与心血管疾病的相关性和机制,并对医生如何劝告高危患者尽可能减少空气污染暴露做出了建议。空气污染可引发近期和远期死亡风险,并可导致包括炎症和动脉粥样硬化在内的不同病理过程。空气污染不局限于室外,大部分空气污染暴露发生于室内,尤其是那些低收入国家,比如用于做饭和供暖的固体燃料。

此外,专家小组还提出了减少室外空气污染暴露的策略,其中包括优选步行、骑自行车和公共交通工具而非小汽车或摩托车;避免在交通量大的街区步行和骑自行车,尤其在高峰时段);在公园锻炼并应避免在主要交通道路进行;严重污染期间限制在室外活动时间,尤其是儿童、老人和心肺疾病患者。


您还可以这样阅读,更多资讯,请关注MedSci微信
  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725703, encodeId=d1c71e2570367, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Feb 03 22:31:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355947, encodeId=b1b1135594efc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472453, encodeId=9b3714e24534a, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562276, encodeId=72f115622e67d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=)]
    2015-02-03 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725703, encodeId=d1c71e2570367, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Feb 03 22:31:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355947, encodeId=b1b1135594efc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472453, encodeId=9b3714e24534a, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562276, encodeId=72f115622e67d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=)]
    2014-12-18 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725703, encodeId=d1c71e2570367, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Feb 03 22:31:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355947, encodeId=b1b1135594efc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472453, encodeId=9b3714e24534a, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562276, encodeId=72f115622e67d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725703, encodeId=d1c71e2570367, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Feb 03 22:31:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355947, encodeId=b1b1135594efc, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472453, encodeId=9b3714e24534a, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562276, encodeId=72f115622e67d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Dec 18 00:31:00 CST 2014, time=2014-12-18, status=1, ipAttribution=)]

相关资讯

ESC 2014:郭艺芳:RDN治疗顽固性高血压何去何从?

肾脏去交感神经治疗(RDN)顽固性高血压技术何去何从?本届ESC年会期间公布了SYMPLICITY HTN-3研究的1年随访结果,仍未发现该技术可使血压降低。目前应如何对待此技术?来自河北省人民医院郭艺芳教授近日在其微博上做了简要的分析,以下为详细内容。近年来,肾脏去交感神经术(RDN)治疗顽固性高血压一直备受关注。 早期研究显示,RDN可以有效降低顽固性高血压患者的血压水平,因而被视为

长城会ESC in China论坛撷英

心衰药物治疗的进展令人惊喜 “多少年来,领域内一直期盼心衰药物治疗的新进展,PARADIM-HF研究给我们带来新惊喜!”ESC前主席Michel Komajda FR教授重点介绍了2014年ESC年会上有关心衰的几项重要研究。PARADIM-HF研究表明,与依那普利相比,兼具ARB和中性内啡肽链酶抑制剂作用的新药LCZ696,可显着降低慢性收缩性心衰患者死亡率和住院率的复合终点发

访CSC-ESC 联合论坛主席霍勇教授

9 月2 日,在今年的ESC年会上,中华医学会心血管病学分会(CSC)再次与ESC合作设立中欧联合论坛,双方共6位专家就急性冠脉综合征(ACS)和高血压相关的3个论题进行了对话与讨论。其中,我国复旦大学附属中山医院葛均波院士、沈阳军区总医院韩雅玲院士和新疆维吾尔自治区人民医院李南方教授分别介绍了接受经皮冠状动脉介入治疗(PCI)的ACS患者的强化他汀负荷、CYP2C19 基因多态性对ACS患者

2014ESC 急性肺栓塞诊断及管理指南解读

近年来,急性肺栓塞领域有关新药物、新治疗、新研究、新探索的证据不断积累,结合临床实际需求,欧洲心脏病学会(ESC)在2014年ESC年会上发布新版《急性肺栓塞诊断及管理指南》(以下简称“新指南”)。新指南在充分考虑诊断和治疗的风险/获益比以及对预后影响的基础上,针对不同的患者推荐最佳管理策略。与2008年版指南相比,新指南在风险评估分层、新型口服抗凝药的使用、特殊问题的处理等方面有较多更新

ESC 2014:周玉杰教授解读急性肺栓塞诊治指南

首都医科大学附属北京安贞医院 周玉杰 刘宇扬 翟光耀 许晓晗 ESC 2014发布了新的急性肺栓塞诊断和管理指南,为临床医师提供了一份高度实用性的针对该领域现存临床证据的总结。在指南的推荐中,主要有三方面的重要变化。 首先,在以患者为核心的治疗策略选择上,危险分层概念得到了强化,同时中危患者的界定进一步清晰化。 第二,指南编写委员会评估了若干近期研究的临床终点数据,对于血压正

ESC 2014:利伐沙班可促房颤患者心脏复律

ESC 2014公布的一项研究表明,在房颤患者中,口服利伐沙班可安全有效的替代维生素K拮抗剂(VKA),并且可促进心脏复律。论文于9月4日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究共纳入1504例房颤患者,并以2:1比率随机给予利伐沙班或VKA治疗。早期和延迟心脏复律策略由研究者选定。主要有效性复合转归由卒中、短暂性脑缺血发作、外周动脉栓塞、心肌梗死和心血管死亡所组成,

Baidu
map
Baidu
map
Baidu
map